OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk — Stella

Recruiting

Back to Breast Cancer trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(2 sites)

South Korea

Gangnam Severance Hospital, Seoul, Korea

Seoul National University Hospital, Seoul

Key details

Phase

Post-approval study

Sponsor

Gangnam Severance Hospital

Collaborators

Seoul National University

Enrollment target

~418 participants

Started

February 2023

Primary completion

January 2031

Age range

20 Years – 50 Years

Sex

Female only

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov